Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsDowngradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.
Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.
